Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.674
-0.016 (-2.30%)
At close: Apr 28, 2026, 4:00 PM EDT
0.700
+0.026 (3.84%)
Pre-market: Apr 29, 2026, 4:00 AM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,085,537
Market Cap
16.81M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
KTTA News
- 27 days ago - Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire